Prothena (NASDAQ:PRTA) Shares Gap Up Following Analyst Upgrade
Prothena (NASDAQ:PRTA) Shares Gap Up Following Analyst Upgrade
Shares of Prothena Co. plc (NASDAQ:PRTA – Get Rating) gapped up prior to trading on Wednesday after Royal Bank of Canada raised their price target on the stock from $45.00 to $52.00. The stock had previously closed at $30.93, but opened at $49.45. Prothena shares last traded at $56.83, with a volume of 67,230 shares.
週三，在加拿大皇家銀行將普羅塞納股份有限公司(納斯達克：PRTA-GET評級)的目標價從45美元上調至52美元后，該公司股價在開盤前大幅上漲。該股此前收盤報30.93美元，開盤報49.45美元。Prothena的股票最後交易價格為56.83美元，成交量為67,230股。
A number of other research firms have also recently commented on PRTA. Bank of America raised shares of Prothena from a "neutral" rating to a "buy" rating and increased their target price for the stock from $45.00 to $65.00 in a report on Wednesday. JMP Securities raised their price objective on shares of Prothena from $50.00 to $81.00 in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $67.75.
其他一些研究公司最近也對PRTA發表了評論。美國銀行週三在一份報告中將普羅塞納的股票評級從中性上調至買入，並將該股目標價從45.00美元上調至65.00美元。JMP證券在週三的一份報告中將Prothena的股票目標價從50.00美元上調至81.00美元。一名股票研究分析師對該股的評級為持有，三名分析師對該公司股票的評級為買入。根據MarketBeat的數據，該股的普遍評級為“適度買入”，平均目標價為67.75美元。
Insider Buying and Selling
內幕買賣
In related news, insider Hideki Garren sold 8,000 shares of the stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $30.00, for a total value of $240,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Hideki Garren sold 8,000 shares of the stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $30.00, for a total value of $240,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Tran Nguyen sold 42,120 shares of the firm's stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $32.49, for a total value of $1,368,478.80. Following the transaction, the chief financial officer now owns 3,200 shares in the company, valued at $103,968. The disclosure for this sale can be found here. Insiders have sold a total of 148,498 shares of company stock worth $4,750,606 in the last ninety days. Corporate insiders own 31.20% of the company's stock.
在相關新聞中，內部人士Hideki Garren在7月6日星期三的一筆交易中出售了8000股該股。這隻股票的平均售價為30.00美元，總價值為240,000.00美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可以通過這個環節。在相關新聞中，內部人士Hideki Garren在7月6日星期三的一筆交易中出售了8000股該股。這隻股票的平均售價為30.00美元，總價值為240,000.00美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可以通過這個環節。此外，CFO Tran Nguyen在7月20日星期三的一筆交易中出售了42,120股該公司的股票。這些股票的平均價格為32.49美元，總價值為1,368,478.80美元。交易完成後，這位首席財務官現在擁有該公司3200股股票，價值103,968美元。關於這次銷售的披露可以找到這裏。在過去的90天裏，內部人士總共出售了148,498股公司股票，價值4,750,606美元。公司內部人士持有該公司31.20%的股份。
Hedge Funds Weigh In On Prothena
對衝基金看好普羅塞納
Prothena Stock Up 87.5 %
普羅塞納股票上漲87.5%
The company has a 50-day simple moving average of $30.70 and a two-hundred day simple moving average of $30.63. The stock has a market cap of $2.72 billion, a P/E ratio of -241.67 and a beta of 1.33.
該公司的50日簡單移動均線切入位在30.70美元，200日簡單移動均線切入位在30.63美元。該股市值為27.2億美元，市盈率為-241.67，貝塔係數為1.33%。
Prothena (NASDAQ:PRTA – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.37). Prothena had a negative net margin of 1.03% and a negative return on equity of 0.33%. The company had revenue of $1.31 million during the quarter, compared to the consensus estimate of $20.12 million. As a group, sell-side analysts forecast that Prothena Co. plc will post -2.57 earnings per share for the current fiscal year.
普羅塞納(納斯達克：PRTA-GET Rating)上一次公佈季度收益數據是在8月8日星期一。這家生物技術公司公佈了本季度每股收益(0.88美元)，低於普遍預期的(0.51美元)和(0.37美元)。普羅塞納的淨利潤率為負1.03%，股本回報率為負0.33%。該公司本季度營收為131萬美元，而市場普遍預期為2012萬美元。賣方分析師預計，普羅塞納公司本財年每股收益將達到2.57歐元。
About Prothena
關於普羅塞納
(Get Rating)
(獲取評級)
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Prothena Corporation plc是一家晚期臨牀公司，專注於在美國發現和開發威脅生命的疾病的新療法。該公司參與開發了治療AL澱粉樣變性的研究性人源化抗體BirTamimab、治療帕金森氏病的人源化單抗Prasinezumab、治療轉甲狀腺素澱粉樣變性的第一階段臨牀試驗的PRX004以及治療阿爾茨海默病的第一階段臨牀試驗的PRX005。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Prothena (PRTA)
- Can HCA Healthcare Weather the Normalization?
- Can United Natural Foods Fight Both Inflation and the Fed?
- Mullen Automotive Is Ready To Get In Gear
- Cracker Barrel: A Tasty Treat Or Bad Apple?
- Defensive Stocks For A Volatile Market
- 免費獲取StockNews.com關於普羅塞納的研究報告(PRTA)
- HCA醫療能否經受住正常化的考驗？
- 聯合天然食品能同時對抗通脹和美聯儲嗎？
- 馬倫汽車已做好準備投入使用
- 餅乾桶：可口的款待還是壞蘋果？
- 防禦性股票應對動盪的市場
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.
接受《普羅塞納日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Prothena和相關公司的最新新聞和分析師評級的每日簡要摘要。